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A B S T R A C T
Isolated splenic metastasis arising from a colorectal carcinoma is a rare finding. We report a case of 74-year-old man
with a medical history od diabetes type II and paroxysmal atrial fibrillation, who underwent a right hemicolectomy for
an adenocarcinoma of caecum in August 2004. In June 2007 the patient was diagnosed with high grade aortic valve ste-
nosis as well as long segment stenosis of the first obtuse marginal branch of left coronary artery. He was suggested aortic
valve replacement with coronary artery bypass grafting but he refused the surgery. In October 2007 the patient underwent
a 18FDG – PET scanning, due to increasing values of CEA serum level, which showed a 5 cm big isolated hypermeta-
bolic lesion in the spleen. Due to operative risk, splenectomy was refused by surgeons. The patient underwent a chemo-
therapy with capecitabine in total of 8 cycles before his CEA level began to rise and MSCT showed a progression in size of
splenic metastasis. The patients condition was reevaluated by a team of experts and splenectomy was performed in Sep-
tember 2008. In May 2009 during the postoperative follow up, MSCT scanning revealed enlarged lymph nodes in celiac
region and hepatic lesion suspicious of metastasis and the patient was addmited for further chemotherapy treatment.
There is still no standardized treatment for this condition due to small number of cases reported in literature. Sple-
nectomy followed by chemotherapy seems to be an optimal treatment but still no final conclusions can be made.
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Introduction
Spleen is an uncommon sight of metastasis of colo-
rectal carcinoma and when diagnosed it is usually a man-
ifestation of disseminated disease1. In November 2007.
group of Italian authors published a case report with a
literature review in which they reported only 42 cases of
isolated splenic metastases originated from colorectum
since the first reported case in 19692,3. Isolated splenic
metastases are very rare due to anatomic factors and the
inhibitory effect of the splenic microenvironment on the
growth of metastatic cells4. The diagnose of solitary
splenic metastasis is usually made by the imaging studies
in the postoperative follow – up period during the evalua-
tion of rising CEA level5. Long-term survival after sple-
nectomy, which is a prefered treatment in these patients,
varied up to 7 years. Considering the fact that splenic
metastases are a form of distant visceral metastasis,
prognosis is rather optimistic6–8. We report the case of
isolated splenic metastasis from colonic carcinoma in a
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patient with severe comorbidities which were the reason
for postponed splenectomy. To the best of our knowledge,
this is a second case of isolated splenic metastasis re-
ported in our contry9 and first case of splenic metastasis
associated with postponed therapeutical splenectomy due
to severe comorbidites reported in a literature.
Case Report
A 74-year-old man with medical history of diabetes
type II and paroxysmal atrial fibrilation had had a right
hemicolectomy for an adenocarcinoma of the caecum in
August 2004. The tumor was clinicaly staged as Dukes C
and the patient underwent a postoperative adjuvant che-
motherapy with Mayo protocol (five cycles od 5-fluoro-
uracil+Leucovorine in doses of 425 mg/m2 and 20 mg/m2
daily for five days). After fifth cycle patient developed fe-
brile neutropenia and pneumonia so the last sixth cycle
was not indicated. He was followed up every six months
with serum CEA level and abdominal ultrasound. In May
2007 his serum CEA level had risen to 38.6 mg/L and ab-
dominal MSCT demonstrated a hypovascular lesion in a
third segment od liver, which was unchanged in the com-
parison to postoperative MSCT scan result. An ultra-
sound guided needle biopsy was performed and cytologi-
cal analysis did not reveal malignant cells. Chest CT scan
and skeleton X-ray were unremarkable. An extensive di-
agnostic workup did not reveal any signs of tumor dis-
semination nor signs of another primary malignant le-
sion. Due to intermittent chest pain the invasive cardial
examination was performed in June 2007 and the patient
was diagnosed with high grade aortic valve stenosis (gra-
dient over aortic valve was 80 mmHg) as well as long seg-
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Fig. 1. F – 18 FDG PET scan demonstrating a hypermetabolic area in upper left abdomen (spleen projection area).
ment stenosis of the first obtuse marginal branch of left
coronary artery. The patient was suggested aortic valve
replacement with coronary artery bypass grafting but he
refused the surgery. In October 2007 the patient under-
went a 18FDG – PET scanning, which showed a 5 cm big
isolated hypermetabolic lesion in the spleen. No other re-
mote organ metastases were found by PET scanning
(Figure 1). Splenectomy was considered but, due to pa-
tients serious heart condition and operative risk, it was
rejected by surgeons. Oncologyst indicated monochemo-
therapy with capecitabine due to patients performance
status (ECOG 1–2) and severe comorbidites. The patient
underwent a first line chemotherapy for metastatic co-
lorectal cancer with capecitabine (total of 8 cycles of
Xeloda in a dose of 2000 mg/m2 from December 2007 to
June 2008). Serum CEA level, before starting the chemo-
therapy, was 245.8 mg/L. He was followed up with serum
CEA level and abdominal MSCT every two cycles and
through the first seven cycles there were no signs of ra-
diological and biochemical progression of the disease.
MSCT performed after eight cycle showed a progression
in size of splenic metastasis to 6 cm and CEA level in-
crease to 363 mg/L (Figure 2). Chemotherapy was stop-
ped as it proved to be ineffective. Due to the fact that the
spleen was still the only sight of the disease splenectomy
was reconsidered. A group of hospital experts including
gastroenterologists, surgeons, cardiologists and anesthe-
siologists discussed the case and decided to offer surgical
treatment to the patient giving him all the informations
about high risks of this treatment. The patient accepted
the risk and underwent splenectomy in September 2008,
almost a year after a first diagnosis of splenic metastasis.
Pathohystological analysis of the resected spleen con-
firmed a metastatic lesion composed of well – differenti-
ated adenocarcinoma cells, 70 mm in diameter, with ne-
crosis in the center. The postoperative recovery was
uneventful. In May 2009 during the postoperative follow
up, MSCT scanning revealed enlarged lymph nodes in ce-
liac region and hepatic lesion suspicious of metastasis. A
cytopunction of enlarged lymph node was performed and
the result was positive to malignant cells. The patient
was addmited to hospital for further chemotherapy treat-
ment.
Discussion
An isolated splenic metastses from colorectal cancer
are a rare finding in a clinical practice. In 1974 Berge
conducted an autopsy examination on 7165 cases with
various cancers and reported an incidence of splenic
metastases as 7.1%, 1019 were cases of colorectal carci-
noma with incidence of splenic metastasis of 4.4%1. An
incidence of isolated splenic metastases was not repor-
ted. A previous studies suggest a few mechanisms which
prohibit the growth of the tumour cells in spleen, includ-
ing anatomical, immunological and pathohistological fea-
tures of the spleen. Tumour cells might disseminate to
spleen haematogenously by retrograd diffusion through
inferior mesenteric vein10, or through the lyphatic sys-
tem11. The sharp angle of the splenic artery with the ce-
liac axis, rythmic contraction by the sinusoidal splenic
architecture and absence of afferent lymphatics to the
spleen are considered to be limiting factors from anatom-
ical point of view7,12. Immunological characteristics of
the spleen, as the second largest organ of the reticuloen-
dothelial system, with profuse monocytes, immunoglobu-
lin synthesis and opsonin production, are also considered
responsible for inhibiting tumour cell proliferation13.
The diagnosis of splenic metastasis can be made by imag-
ing studies during the diagnostic workup for colorectal
cancer5. The literature review shows that majority of re-
ported patiens with isolated splenic metastasis were
asimptomatic at the time of diagnosis and the only sign
of active disease was elevated carcinoembryonic antigen
(CEA) level. As Kim JC suggested in his studies, CEA ap-
pears as an immunosuppressant and acts as an adhesion
molecule between cancer cells and visceral macrophages,
so colonic tumour cells with positive CEA staining should
behave more aggressive and could be associated with the
occurence of isolated splenic metastases12,14. The major-
ity of patients with isolated metachronous splenic metas-
tasis reported in the literature underwent curative sple-
nectomy and long – term survival varied from 0.5 to 7
years6–8. Most of previously mentioned patients have had
a disease free survival of 3 to 144 months after the pri-
mary colorectal tumour6,15. It is been reported that the
patiens with syncronous splenic metastasis have much
worse prognosis and shorter disease free survival2,6.
Conclusion
Isolated splenic metastasis from colonic cancer is a
rarity in clinical practise. There is no standardized treat-
ment for this condition due to small number of cases re-
ported in literature. Splenectomy followed by chemo-
therapy tends to be an optimal therapeutical approach
but still no final conclusions can be made.
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Fig. 2. MSCT demonstrates a low – attenuation area in the sple-
nic area.
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IZOLIRANA METASTAZA KOLOREKTALNOG KARCINOMA U SLEZENU
U VISOKORIZI^NOG BOLESNIKA: PRIKAZ SLU^AJA
S A @ E T A K
Izolirane metastaze kolorektalnog karcinoma u slezenu su rijetkost. U ~lanku prezentiramo slu~aj 74-godi{njeg
mu{karca s poznatom anamnezom dijabetesa tipa II i paroksizmalne fibrilacije atrija, kojemu je, u kolovozu 2004. go-
dine, u~injena desnostrana hemikolektomija zbog adenokarcinoma cekuma. U lipnju 2007. godine bolesniku je dijagno-
sticirana te{ka aortalna stenoza, kao i dugopotezna stenoza prve marginalne grane lijeve koronarne arterije. Predlo-
`ena mu je operacija zamjene aortnog zaliska uz aortokoronarno premo{tenje, no odbio je operativni zahvat. U listo-
padu 2007. godine bolesniku je, zbog porasta vrijednosti serumskog CEA, u~injen 18FDG – PET sken koji je pokazao 5
cm veliku izoliranu hipermetaboli~ku leziju u slezeni. Slu~aj je prezentiran kirurzima koji se, zbog komorbiditeta i
operativnog rizika, nisu odlu~ili za zahvat splenektomije. Provedena je kemoterapija kapecitabinom u 8 ciklusa nakon
~ega su vrijednosti serumskog CEA ponovno po~ele rasti, a kontrolni MSCT je pokazao progresiju veli~ine metastaze.
Tim stru~njaka je reevaluirao cijeli slu~aj te je u rujnu 2008. godine bolesniku u~injena splenektomija. U svibnju 2009.
godine, tijekom postoperativnog pra}enja, kontrolni MSCT je pokazao uve}ane limfne ~vorove u celija~noj regiji i sus-
pektnu jetrenu metastazu nakon ~ega je bolesnik hospitaliziran na daljnje kemoterapijsko lije~enje. Jo{ uvijek ne
postoji standardizirano lije~enje predvi|eno za ovakve bolesnike zahvaljuju}i malom broju slu~ajeva koji su opisani u
literaturi. Splenektomija pra}ena kemoterapijom je vjerojatno optimalan slijed lije~enja, ali kona~ni zaklju~ci, odnosno
smjernice lije~enja, se jo{ ne mogu donijeti.
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